Sandramycin
Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 100940-65-6
- Formula: C60H76N12O16
- Molecular Weight:1221.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
|
Traditional Cytotoxic Agents |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
8 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| B16 | IC50 |
0.4 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
|
10.1016/S0960-894X(97)00129-7 |
| BT-549 | IC50 |
1 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| EBC-1 | IC50 |
1.4 nM
Compound: Sandramycin
|
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
|
[PMID: 37307297] |
| H322 | IC50 |
20 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| HL-60 | IC50 |
80 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
|
10.1016/S0960-894X(97)00129-7 |
| HT-29 | IC50 |
1 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| IGROV-1 | IC50 |
1.6 nM
Compound: Sandramycin
|
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
|
[PMID: 37307297] |
| L1210 | IC50 |
0.02 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
|
10.1016/S0960-894X(97)00129-7 |
| MCF7 | IC50 |
300 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| MOLT-4 | IC50 |
0.7 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
|
10.1016/S0960-894X(97)00129-7 |
| OVCAR-3 | IC50 |
1 nM
Compound: Sandramycin
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
|
[PMID: 37307297] |
| OVCAR-3 | IC50 |
4 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| PC-3 | IC50 |
0.2 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| SiHa | IC50 |
0.3 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
|
10.1016/S0960-894X(97)00129-7 |
| SK-MEL-28 | IC50 |
1 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
|
10.1016/S0960-894X(97)00129-7 |
| UCLA P-3 | IC50 |
10 nM
Compound: 1 (Sandramycin)
|
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
|
10.1016/S0960-894X(97)00129-7 |
Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec+) A22508-2, B. subtilis (Rec-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC50 values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CDF1 female mice injected with leukemia P388 cells[1]
-
Dosage:0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg
-
Administration:Intraperitoneal injection; daily; for 5 days
-
Result:Was moderately active in vivo against leukemia P388 in mice.
Chemical Information
-
CAS No. 100940-65-6
-
Molecular Weight 1221.32
-
Formula C60H76N12O16
-
SMILES
CC(C)[C@@H](C(OC[C@@H](NC(C1=C(O)C=C(C=CC=C2)C2=N1)=O)C3=O)=O)N(C)C(CN(C)C(CNC([C@@H]4CCCCN4C([C@@H](COC([C@H](C(C)C)N(C)C(CN(C)C(CNC([C@H]5N3CCCC5)=O)=O)=O)=O)NC(C6=C(O)C=C(C=CC=C7)C7=N6)=O)=O)=O)=O)=O
-
Structure Classification
-
Initial Source
Nocardioides sp.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. J A Matson, et al. Sandramycin, a Novel Antitumor Antibiotic Produced by a Nocardioides Sp. Production, Isolation, Characterization and Biological Properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7. [Content Brief]
[2]. Katsushi Katayama, et al. Total Synthesis of Sandramycin and Its Analogues via a Multicomponent Assemblage. Org Lett. 2014 Jan 17;16(2):428-31. [Content Brief]
[3]. D L Boger, et al. DNA Binding Properties of Key Sandramycin Analogues: Systematic Examination of the Intercalation Chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sandramycin Related Classifications
HY-19829 Related Classifications
Powered by Bioz